{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T01:42:33Z","timestamp":1721871753886},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Public Health"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.puhe.2008.04.009","type":"journal-article","created":{"date-parts":[[2008,8,16]],"date-time":"2008-08-16T06:56:58Z","timestamp":1218869818000},"page":"1356-1362","source":"Crossref","is-referenced-by-count":7,"title":["Selective serotonin re-uptake inhibitor warnings and trends in exposures reported to poison control centres in Texas"],"prefix":"10.1016","volume":"122","author":[{"given":"M.B.","family":"Forrester","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.puhe.2008.04.009_bib1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/bmj.324.7332.260","article-title":"Withdrawal from paroxetine can be severe, warns FDA","volume":"324","author":"Tonks","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.puhe.2008.04.009_bib2","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/bmj.326.7402.1282-b","article-title":"Paroxetine must not be given to patients under 18","volume":"326","author":"Waechter","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.puhe.2008.04.009_bib3","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(03)14787-3","article-title":"FDA questions antidepressant safety for children","volume":"362","author":"Oransky","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.puhe.2008.04.009_bib4","series-title":"FDA statement regarding the anti-depressant Paxil for pediatric population","author":"Food and Drug Administration","year":"2003"},{"key":"10.1016\/j.puhe.2008.04.009_bib5","series-title":"FDA public health advisory. Reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD)","author":"Food and Drug Administration","year":"2003"},{"key":"10.1016\/j.puhe.2008.04.009_bib6","series-title":"FDA public health advisory. Worsening depression and suicidality in patients being treated with antidepressant","author":"Food and Drug Administration","year":"2004"},{"key":"10.1016\/j.puhe.2008.04.009_bib7","series-title":"FDA public health advisory. Suicidality in children and adolescents being treated with antidepressant medications","author":"Food and Drug Administration","year":"2004"},{"key":"10.1016\/j.puhe.2008.04.009_bib8","series-title":"Paxil (paroxetine HCL). Paxil CR controlled-release tablets","author":"Food and Drug Administration","year":"2005"},{"key":"10.1016\/j.puhe.2008.04.009_bib9","unstructured":"GlaxoSmithKline. Study EPIP083 \u2013 preliminary report. GlaxoSmithKline; 2005. http:\/\/ctr.gsk.co.uk\/Summary\/paroxetine\/studylist.asp (last accessed 25November 2007)."},{"key":"10.1016\/j.puhe.2008.04.009_bib10","unstructured":"GlaxoSmithKline. Study EPIP083 \u2013 updated preliminary report. GlaxoSmithKline; 2005. http:\/\/ctr.gsk.co.uk\/Summary\/paroxetine\/studylist.asp (last accessed 25 November 2007)."},{"key":"10.1016\/j.puhe.2008.04.009_bib11","series-title":"FDA advising of risk of birth defects with Paxil. Agency requiring updated product labeling","author":"Food and Drug Administration","year":"2005"},{"key":"10.1016\/j.puhe.2008.04.009_bib12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2125.2005.02527.x","article-title":"Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001\u20132004","volume":"61","author":"Martin","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.puhe.2008.04.009_bib13","series-title":"Safety of Seroxat (paroxetine) in children and adolescents under 18 years \u2013 contraindication in the treatment of depressive illness","author":"Duff","year":"2003"},{"key":"10.1016\/j.puhe.2008.04.009_bib14","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2105\/AJPH.2006.087262","article-title":"The effect of antidepressant warnings on prescribing trends in Ontario, Canada","volume":"97","author":"Kurdyak","year":"2007","journal-title":"Am J Public Health"},{"key":"10.1016\/j.puhe.2008.04.009_bib15","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2165\/00002018-200528120-00009","article-title":"Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK","volume":"28","author":"Murray","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.puhe.2008.04.009_bib16","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/pds.1396","article-title":"Antidepressants in children and adolescents \u2013 changes in utilisation after safety warnings","volume":"16","author":"Dean","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.puhe.2008.04.009_bib17","article-title":"Study finds less youth antidepressant use","volume":"21","author":"Harris","year":"2004","journal-title":"New York Times"},{"key":"10.1016\/j.puhe.2008.04.009_bib18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archpsyc.64.4.466","article-title":"Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States","volume":"64","author":"Nemeroff","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.puhe.2008.04.009_bib19","first-page":"1,39","article-title":"New data show declines in antidepressant prescribing","volume":"40","author":"Rosack","year":"2005","journal-title":"Psychiatr News"},{"key":"10.1016\/j.puhe.2008.04.009_bib20","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/15563650600907165","article-title":"2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database","volume":"44","author":"Lai","year":"2006","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.puhe.2008.04.009_bib21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ajem.2005.05.001","article-title":"2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System","volume":"23","author":"Watson","year":"2005","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.puhe.2008.04.009_bib22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ajem.2004.06.001","article-title":"2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System","volume":"22","author":"Watson","year":"2004","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.puhe.2008.04.009_bib23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0735-6757(03)00088-3","article-title":"2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System","volume":"21","author":"Watson","year":"2003","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.puhe.2008.04.009_bib24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1053\/ajem.2002.34955","article-title":"2001 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System","volume":"20","author":"Litovitz","year":"2002","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.puhe.2008.04.009_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/ajem.2001.25272","article-title":"2000 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System","volume":"19","author":"Litovitz","year":"2001","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.puhe.2008.04.009_bib26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1053\/ajem.2000.9261","article-title":"1999 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System","volume":"18","author":"Litovitz","year":"2000","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.puhe.2008.04.009_bib27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0735-6757(99)90254-1","article-title":"1998 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System","volume":"17","author":"Litovitz","year":"1999","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.puhe.2008.04.009_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/02772240701407052","article-title":"Impact of withdrawal from market on the pattern of cyclocygenase-2 inhibitors reported to Texas poison control centers","volume":"90","author":"Forrester","year":"2008","journal-title":"J Toxicol Environ Chem"},{"key":"10.1016\/j.puhe.2008.04.009_bib29","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","article-title":"Timing of new black box warnings and withdrawals for prescription medications","volume":"287","author":"Lasser","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.puhe.2008.04.009_bib30","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archinte.166.3.338","article-title":"Adherence to black box warnings for prescription medications in outpatients","volume":"166","author":"Lasser","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.puhe.2008.04.009_bib31","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4065\/82.4.518","article-title":"Impact of the FDA black box warning on physician antidepressant prescribing and practice patterns: opening Pandora's suicide box","volume":"82","author":"Lineberry","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.puhe.2008.04.009_bib32","first-page":"247","article-title":"Calls about anthrax to the Texas Poison Center Network in relation to the anthrax bioterrorism attack in 2001","volume":"45","author":"Forrester","year":"2003","journal-title":"Vet Hum Toxicol"}],"container-title":["Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033350608001121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033350608001121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T06:51:20Z","timestamp":1545807080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033350608001121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0033350608001121"],"URL":"https:\/\/doi.org\/10.1016\/j.puhe.2008.04.009","relation":{},"ISSN":["0033-3506"],"issn-type":[{"value":"0033-3506","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}